Human Respiratory Syncytial Virus
Human Respiratory Syncytial Virus is one of the most abundant infections caused in the Lungs and Respiratory Tract. It is most common that affect children and most severity in adults. hRSV usually attacks severely the babies lesser than 12 months especially premature babies and in adults those who are immuno-compromised. There was no vaccine prepared till now. Nowadays natural products play a vast role and major role in the drug research. Quercetin which is one of the natural products has a property of anti-oxidant plays a crucial role in drug research.
Proposed Idea
Our idea is to produce a drug by acetylating quercetin into its derivatives and to bind it with the protein present in the hRSV and to inhibit with help of it. Till now several investigations have been done and structural modifications have been given on natural products.
The rationale of our proposal lies in the selection of this particular composite because there is no previous report/study/literature on this combination. It is most common that affect children and most severity in adults.
hRSV usually attacks severely the babies lesser than 12 months especially premature babies and in adults those who are immuno-compromised. hRSV is made up of a helical symmetry nucleocapsid and a lipid envelope, and its genome is made up of a non-segmented, single-stranded negative sense RNA with ten coding genes that encode eleven proteins (Source: https://pubmed.ncbi.nlm.nih.gov/29292149/).
To date, there is no proper drug and treatment are only available periodically. There are many natural products available which are huge responsible for the inhibition process of hRSV. Though the usual treatment is not efficient, there are many therapies found for the hRSV.
The major idea of this study is to develop a drug and to identify the route of drug administration made up of quercetin. Quercetin belongs to the flavonoid classes, when it is acetylated, it gives peraacetylated-quercetin and tetra acetylated quercetin (Source: https://pubmed.ncbi.nlm.nih.gov/31712123/).
Why Quercetin?
Quercetin is the natural polymer which comes under the flavonoids has potential antibacterial and antiviral activity against major viruses like Hepatitis B, Polio Virus Type-I. When this Quercetin is acetylated, it gives its derivatives Pera acetylated Quercetin and Tetra acetylated Quercetin which are prone to larger bioavailability.
We already know that quercetin has anti-inflammatory and anti-oxidant property. By exploiting this property, we hypothesize that the binding of M2-1 protein with Quercetin derivatives against potential oxidation. The rationale of our proposal lies in the selection of this particular composite because there is no previous report/study/literature on this combination.
By formulating this we are trying to develop a potential drug by interacting quercetin derivatives with the RNA binding sites of M2-1 proteins which inhibits the hRSV. This binding may result in the improving properties of a new vital drug.
The interaction between the Quercetin derivatives (Q1 and Q2) and M2-1 Proteins is highly expected with affinity constants. The cytocompatibility of the compound in positive approach is also expected.
The newer way of interaction of the drug with the route of administration via veins may improve the properties of the new material. It is accelerated to improve the progress in the animal models.
Conclusion
We strongly believe that the newer way of drug administration was adopted using this method. This progress can give more application-oriented research for the future problems. hRSV is one of the most common viruses occurs in children and in some adults of age more than 65 years.
We also conclude that the progress of this research work will reduce the cytotoxicity effect if done properly. Quercetin has an ability of antiviral agent; hence it also possesses antiviral activity of the virus. Hence the effect of the infection can be much reduced and future progress can also be carried out regarding hRSV virus.
Featured Image Source: https://thenativeantigencompany.com/products/respiratory-syncytial-virus-a-glycoprotein-g-human-fc-tag-copy/